Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10506693rdf:typepubmed:Citationlld:pubmed
pubmed-article:10506693lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:10506693lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:10506693lifeskim:mentionsumls-concept:C0278701lld:lifeskim
pubmed-article:10506693lifeskim:mentionsumls-concept:C0032207lld:lifeskim
pubmed-article:10506693lifeskim:mentionsumls-concept:C0282460lld:lifeskim
pubmed-article:10506693lifeskim:mentionsumls-concept:C0243071lld:lifeskim
pubmed-article:10506693lifeskim:mentionsumls-concept:C0205179lld:lifeskim
pubmed-article:10506693lifeskim:mentionsumls-concept:C0291493lld:lifeskim
pubmed-article:10506693pubmed:issue7lld:pubmed
pubmed-article:10506693pubmed:dateCreated1999-10-18lld:pubmed
pubmed-article:10506693pubmed:abstractTextSKI-2053R (SK Chemicals, Kyungki-Do, South Korea) is a new platinum derivative with antitumor activity against various cell lines, including cisplatin-resistant tumor cell lines. Preclinical studies have suggested that it is less nephrotoxic than cisplatin. This study evaluated the efficacy and toxicity of SKI-2053R in the treatment of patients with advanced gastric adenocarcinoma.lld:pubmed
pubmed-article:10506693pubmed:languageenglld:pubmed
pubmed-article:10506693pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10506693pubmed:citationSubsetAIMlld:pubmed
pubmed-article:10506693pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10506693pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10506693pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10506693pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10506693pubmed:statusMEDLINElld:pubmed
pubmed-article:10506693pubmed:monthOctlld:pubmed
pubmed-article:10506693pubmed:issn0008-543Xlld:pubmed
pubmed-article:10506693pubmed:authorpubmed-author:KeyI DIDlld:pubmed
pubmed-article:10506693pubmed:authorpubmed-author:PALS NSNlld:pubmed
pubmed-article:10506693pubmed:authorpubmed-author:KimN KNKlld:pubmed
pubmed-article:10506693pubmed:authorpubmed-author:LeeM HMHlld:pubmed
pubmed-article:10506693pubmed:authorpubmed-author:KimD WDWlld:pubmed
pubmed-article:10506693pubmed:authorpubmed-author:CaseF HFH3rdlld:pubmed
pubmed-article:10506693pubmed:authorpubmed-author:WenW NWNlld:pubmed
pubmed-article:10506693pubmed:authorpubmed-author:ROYM YMYlld:pubmed
pubmed-article:10506693pubmed:authorpubmed-author:NoeTTlld:pubmed
pubmed-article:10506693pubmed:authorpubmed-author:JungC WCWlld:pubmed
pubmed-article:10506693pubmed:copyrightInfoCopyright 1999 American Cancer Society.lld:pubmed
pubmed-article:10506693pubmed:issnTypePrintlld:pubmed
pubmed-article:10506693pubmed:day1lld:pubmed
pubmed-article:10506693pubmed:volume86lld:pubmed
pubmed-article:10506693pubmed:ownerNLMlld:pubmed
pubmed-article:10506693pubmed:authorsCompleteYlld:pubmed
pubmed-article:10506693pubmed:pagination1109-15lld:pubmed
pubmed-article:10506693pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:10506693pubmed:meshHeadingpubmed-meshheading:10506693...lld:pubmed
pubmed-article:10506693pubmed:meshHeadingpubmed-meshheading:10506693...lld:pubmed
pubmed-article:10506693pubmed:meshHeadingpubmed-meshheading:10506693...lld:pubmed
pubmed-article:10506693pubmed:meshHeadingpubmed-meshheading:10506693...lld:pubmed
pubmed-article:10506693pubmed:meshHeadingpubmed-meshheading:10506693...lld:pubmed
pubmed-article:10506693pubmed:meshHeadingpubmed-meshheading:10506693...lld:pubmed
pubmed-article:10506693pubmed:meshHeadingpubmed-meshheading:10506693...lld:pubmed
pubmed-article:10506693pubmed:meshHeadingpubmed-meshheading:10506693...lld:pubmed
pubmed-article:10506693pubmed:meshHeadingpubmed-meshheading:10506693...lld:pubmed
pubmed-article:10506693pubmed:meshHeadingpubmed-meshheading:10506693...lld:pubmed
pubmed-article:10506693pubmed:meshHeadingpubmed-meshheading:10506693...lld:pubmed
pubmed-article:10506693pubmed:year1999lld:pubmed
pubmed-article:10506693pubmed:articleTitlePhase II clinical trial of SKI-2053R, a new platinum analog, in the treatment of patients with advanced gastric adenocarcinoma.lld:pubmed
pubmed-article:10506693pubmed:affiliationDepartment of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea.lld:pubmed
pubmed-article:10506693pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10506693pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:10506693pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:10506693pubmed:publicationTypeClinical Trial, Phase IIlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10506693lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10506693lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10506693lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10506693lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10506693lld:pubmed